{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T10:56:38Z","timestamp":1791543398806,"version":"4.3.4"},"reference-count":9,"publisher":"European Respiratory Society (ERS)","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2026,7,14]]},"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1183\/13993003.01322-2026","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T10:35:20Z","timestamp":1791542120000},"page":"2601322","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Reply to: Real-world safety signals of isoniazid in adults and children: a complementary FAERS analysis to inform paediatric dose optimisation"],"prefix":"10.1183","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9751-8249","authenticated-orcid":false,"given":"Agathe","family":"B\u00e9ranger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n P.","family":"Solans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3143-5579","authenticated-orcid":false,"given":"Radojka M.","family":"Savic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"2026100903351241000_68.4.2601322.1","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1111\/cts.13305","article-title":"Tutorial: statistical analysis and reporting of clinical pharmacokinetic studies","volume":"15","author":"Dunvald","year":"2022","journal-title":"Clin Transl Sci"},{"key":"2026100903351241000_68.4.2601322.2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01046-2025"},{"key":"2026100903351241000_68.4.2601322.3","unstructured":"Electronic Medicines Compendium . Isoniazid 50\u2005mg Tablets BP: Summary of Product Characteristics. Date last accessed: 4 June 2026. Date last updated: 29 August 2025. www.medicines.org.uk\/emc\/product\/9138\/smpc#gref"},{"key":"2026100903351241000_68.4.2601322.4","unstructured":"US Food and Drug Administration . RIFATER\u00ae (Rifampin, Isoniazid and Pyrazinamide) Tablets Label. Date last accessed: 4 June 2026. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/050705s029lbl.pdf"},{"key":"2026100903351241000_68.4.2601322.5","first-page":"139","article-title":"A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis","volume":"12","author":"Katiyar","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026100903351241000_68.4.2601322.6","doi-asserted-by":"crossref","first-page":"e70204","DOI":"10.1002\/ardp.70204","article-title":"A review on isoniazid and rifampicin-associated hepatotoxicity: from metabolism to immunity","volume":"359","author":"Batool","year":"2026","journal-title":"Arch Pharm (Weinheim)"},{"key":"2026100903351241000_68.4.2601322.7","doi-asserted-by":"crossref","unstructured":"Yang E , Van Brantegem P , Peloquin CA , et al. Pharmacokinetic and pharmacogenomic predictors of hepatotoxicity in the HIRIF trial for drug-susceptible tuberculosis. Clin Infect Dis 2026; in press [https:\/\/doi.org\/10.1093\/cid\/ciag141].","DOI":"10.1093\/cid\/ciag141"},{"key":"2026100903351241000_68.4.2601322.8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.25259\/IJMR_1673_2024","article-title":"Efficacy & safety of high-dose rifampicin in pulmonary tuberculosis: a systematic review & meta-analysis","volume":"161","author":"Kannabiran","year":"2025","journal-title":"Indian J Med Res"},{"key":"2026100903351241000_68.4.2601322.9","unstructured":"World Health Organization . Global Tuberculosis Report 2025. Geneva, World Health Organization, 2025."}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01322-2026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T10:35:22Z","timestamp":1791542122000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01322-2026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":9,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,10,9]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1183\/13993003.01322-2026"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01322-2026","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}